Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Generalized convulsive status epilepticus Clinical criteria: Treatment Phase: Initial treatment Patient must have been assessed to be at significant risk of status epilepticus, AND Patient must have experienced at least one prolonged seizure (greater than 5 minutes duration) requiring emergency medical attention within the previous 5 years. Population criteria: Patient must be at least one year of age. The treatment must initiated by a specialist physician experienced in the treatment of epilepsy. At the time of the authority application, medical practitioners should request the appropriate quantity to cater for the patient's circumstances. Up to a maximum of 10 syringes for each prescription can be authorised for patients with high frequency seizures.
“Midazolam is a short-acting central nervous system depressant which induces sedation, hypnosis, amnesia and anaesthesia.”
“In normal subjects the mean elimination half-life of midazolam is between 1.4 – 2.4 h and the clearance is in the range of 220 – 470 mL/min.”
“Midazolam is almost exclusively metabolised by CYP3A (primarily CYP 3A4 and also CYP 3A5).”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.